INBX (Inhibrx Biosciences) צמיחת רווח נקי למניה השנה

Inhibrx Biosciences (INBX) relies on external contractors for manufacturing and testing to maintain workforce flexibility. The YoY net income per share trend on GURU.Markets shows a figure at -5.30, which offsets market noise. Management is skillfully investing cash following the deal with Sanofi, although the lack of stable revenue leaves the company dependent on new funding rounds.

Investors are assessing the financial stability of Inhibrx Biosciences (INBX) through earnings per share (EPS) dynamics, which measure the annual growth rate of net income per share. By analyzing the percentage deviation of EPS from the previous year's level, one can determine how effectively the proprietary single-domain antibody technology converts into profit growth and ensures high business margins.